United Therapeutics Corporation (UTHR)

Import this data to Google Sheets with:

=jivedata("UTHR","financials")

Full statements spill as a table. For one cell: =jivedata("UTHR","Revenue") or =jivedata("UTHR","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

United Therapeutics Corporation

UTHR • CIK 0001082554

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Revenue from Contract with Customer, Excluding Assessed Tax	$2,327,500	$2,877,400	$3,182,700	$3,154,500
Operating Income (Loss)	$1,184,900	$1,377,000	$1,492,500	$1,401,800
Investment Income, Interest	$162,700	$199,100	$192,000	$162,900
InterestExpenseNonoperating	—	$42,900	$19,500	$12,000
Other Nonoperating Income (Expense)	$-14,000	$5,800	$48,900	$20,300
Nonoperating Income (Expense)	$89,400	$162,000	$221,400	$171,200
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$1,274,300	$1,539,000	$1,713,900	$1,573,000
Income Tax Expense (Benefit)	$289,500	$343,900	$379,200	$262,100
Net Income (Loss) Attributable to Parent	$984,800	$1,195,100	$1,334,700	$1,310,900
Cost of Goods and Services Sold	$257,500	$309,700	$384,400	$437,200
Research and Development Expense	$408,000	$481,000	$550,000	$551,500
Selling, General and Administrative Expense	$477,100	$709,700	$755,800	$764,000
Costs and Expenses	$1,142,600	$1,500,400	$1,690,200	$1,752,700
Weighted Average Number of Shares Outstanding, Basic	46,800,000	45,200,000	44,300,000	42,300,000
Weighted Average Number of Shares Outstanding, Diluted	49,700,000	48,500,000	47,900,000	45,900,000

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Cash and Cash Equivalents, at Carrying Value	$1,207,700	$1,697,200	$1,557,100	$1,803,200
Marketable Securities, Current	$1,786,400	$1,569,800	$1,363,200	$859,100
Marketable Securities, Noncurrent	$1,909,800	$1,475,300	$1,776,700	$1,141,100
Accounts Receivable, after Allowance for Credit Loss, Current	$278,900	$279,300	$350,200	$310,300
Intangible Assets, Net (Including Goodwill)	$114,200	$111,900	$116,500	$114,100
Inventory, Net	$111,800	$157,900	$183,100	$193,800
Property, Plant and Equipment, Net	$1,045,400	$1,222,400	$1,729,700	$1,930,100
Other Assets, Current	$166,200	$169,700	$248,900	$317,300
Deferred Income Tax Assets, Net	$394,800	$458,400	$357,700	$311,600
Assets, Current	$3,551,000	$3,873,900	$3,702,500	$3,483,700
Other Assets, Noncurrent	$151,800	$222,100	$196,900	$239,500
Assets	$7,167,000	$7,364,000	$7,880,000	$7,220,100
Other Liabilities, Noncurrent	$77,800	$181,900	$223,200	$212,000
Liabilities	$1,182,200	$920,000	$783,800	$819,800
Accounts Payable and Accrued Liabilities, Current	$298,000	$344,500	$488,000	$497,800
Line of Credit, Current	$400,000	$300,000	$0	$0
Other Liabilities, Current	$71,000	$82,600	$72,600	$110,000
Liabilities, Current	$804,400	$738,100	$560,600	$607,800
Preferred Stock, Value, Issued	$0	$0	$0	$0
Common Stock, Value, Issued	$700	$800	$800	$800
Additional Paid in Capital, Common Stock	$2,549,000	$2,698,900	$2,798,000	$2,895,800
Accumulated Other Comprehensive Income (Loss), Net of Tax	$-12,800	$-3,400	$900	$-16,200
Treasury Stock, Common, Value	$2,579,200	$3,474,500	$4,260,400	$5,644,900
Retained Earnings (Accumulated Deficit)	$6,027,100	$7,222,200	$8,556,900	$9,164,800
Stockholders' Equity Attributable to Parent	$5,984,800	$6,444,000	$7,096,200	$6,400,300
Preferred Stock, Shares Authorized	10,000,000	10,000,000	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0	0	0
Common Stock, Shares Authorized	245,000,000	245,000,000	245,000,000	245,000,000
Common Stock, Shares, Issued	73,659,761	74,997,896	76,452,253	78,029,318
Common Stock, Shares, Outstanding	47,040,545	44,831,306	43,643,165	42,676,835
Treasury Stock, Common, Shares	26,619,216	30,166,590	32,809,088	35,352,483

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Net Income (Loss) Attributable to Parent	$984,800	$1,195,100	$1,334,700	$1,310,900
Net Cash Provided by (Used in) Operating Activities	$978,000	$1,327,100	$1,561,200	$1,685,200
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	$246,500	$489,500	$-140,100	$210,100
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$1,207,700	$1,697,200	$1,557,100	$936,900
Depreciation, Depletion and Amortization	$53,200	$72,500	$85,600	$91,500
Payments to Acquire Property, Plant, and Equipment	$230,400	$246,500	$520,500	$592,200
Share-based Payment Arrangement, Noncash Expense	$39,100	$144,000	$147,700	$155,400
Payments to Acquire Intangible Assets	—	—	$5,500	$5,500
Impairment of Long-Lived Assets Held-for-use	$3,600	$0	$21,700	$21,700
Deferred Income Tax Expense (Benefit)	$-64,400	$-64,100	$97,700	$149,300
Payments to Acquire Debt Securities, Available-for-sale	$2,514,300	$1,646,100	$3,405,400	$1,677,000
Other Noncash Income (Expense)	$4,900	$24,300	$19,700	$-23,100
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale	$2,137,300	$1,537,000	$1,583,900	$1,202,300
Proceeds from Sale of Debt Securities, Available-for-sale	$0	$831,800	$1,861,600	$1,903,900
Payments to Acquire Businesses, Net of Cash Acquired	$89,200	$0	$0	$0
Net Cash Provided by (Used in) Investing Activities	$-719,600	$417,200	$-551,300	$744,500
Increase (Decrease) in Accounts Receivable	$58,500	$400	$70,900	$-69,000
Payments for Repurchase of Common Stock	—	$1,000,000	$1,000,000	$2,500,000
Increase (Decrease) in Inventories	$13,600	$46,900	$52,600	$91,800
Proceeds from Lines of Credit	$0	$0	$200,000	$0
Increase (Decrease) in Accounts Payable and Accrued Liabilities	$57,100	$42,700	$97,900	$37,700
Repayments of Lines of Credit	$100,000	$400,000	$500,000	$0
Increase (Decrease) in Other Operating Assets and Liabilities, Net	$82,800	$55,600	$80,900	$108,100
Payments of Debt Issuance Costs	$2,700	$2,700	$11,500	$3,400
Proceeds from Stock Options Exercised	$98,000	$152,500	$173,900	$333,800
Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised	$6,600	$7,600	$9,200	$9,900
Payment, Tax Withholding, Share-based Payment Arrangement	$13,800	$12,200	$16,600	$59,900
Net Cash Provided by (Used in) Financing Activities	$-11,900	$-1,254,800	$-1,150,000	$-2,219,600
Interest Paid, Excluding Capitalized Interest, Operating Activities	$56,000	$40,200	$13,500	$7,700
Income Taxes Paid, Net	$332,500	$400,600	$313,300	$161,900
Capital Expenditures Incurred but Not yet Paid	$18,400	$22,200	$116,300	$154,200

Jive Data

Google Sheets add-onSheets Account

Import this data to Google Sheets with:

=jivedata("UTHR","financials")

Full statements spill as a table. For one cell: =jivedata("UTHR","Revenue") or =jivedata("UTHR","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

United Therapeutics Corporation

UTHR • CIK 0001082554

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Revenue from Contract with Customer, Excluding Assessed Tax	$2,327,500	$2,877,400	$3,182,700	$3,154,500
Operating Income (Loss)	$1,184,900	$1,377,000	$1,492,500	$1,401,800
Investment Income, Interest	$162,700	$199,100	$192,000	$162,900
InterestExpenseNonoperating	—	$42,900	$19,500	$12,000
Other Nonoperating Income (Expense)	$-14,000	$5,800	$48,900	$20,300
Nonoperating Income (Expense)	$89,400	$162,000	$221,400	$171,200
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$1,274,300	$1,539,000	$1,713,900	$1,573,000
Income Tax Expense (Benefit)	$289,500	$343,900	$379,200	$262,100
Net Income (Loss) Attributable to Parent	$984,800	$1,195,100	$1,334,700	$1,310,900
Cost of Goods and Services Sold	$257,500	$309,700	$384,400	$437,200
Research and Development Expense	$408,000	$481,000	$550,000	$551,500
Selling, General and Administrative Expense	$477,100	$709,700	$755,800	$764,000
Costs and Expenses	$1,142,600	$1,500,400	$1,690,200	$1,752,700
Weighted Average Number of Shares Outstanding, Basic	46,800,000	45,200,000	44,300,000	42,300,000
Weighted Average Number of Shares Outstanding, Diluted	49,700,000	48,500,000	47,900,000	45,900,000

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Cash and Cash Equivalents, at Carrying Value	$1,207,700	$1,697,200	$1,557,100	$1,803,200
Marketable Securities, Current	$1,786,400	$1,569,800	$1,363,200	$859,100
Marketable Securities, Noncurrent	$1,909,800	$1,475,300	$1,776,700	$1,141,100
Accounts Receivable, after Allowance for Credit Loss, Current	$278,900	$279,300	$350,200	$310,300
Intangible Assets, Net (Including Goodwill)	$114,200	$111,900	$116,500	$114,100
Inventory, Net	$111,800	$157,900	$183,100	$193,800
Property, Plant and Equipment, Net	$1,045,400	$1,222,400	$1,729,700	$1,930,100
Other Assets, Current	$166,200	$169,700	$248,900	$317,300
Deferred Income Tax Assets, Net	$394,800	$458,400	$357,700	$311,600
Assets, Current	$3,551,000	$3,873,900	$3,702,500	$3,483,700
Other Assets, Noncurrent	$151,800	$222,100	$196,900	$239,500
Assets	$7,167,000	$7,364,000	$7,880,000	$7,220,100
Other Liabilities, Noncurrent	$77,800	$181,900	$223,200	$212,000
Liabilities	$1,182,200	$920,000	$783,800	$819,800
Accounts Payable and Accrued Liabilities, Current	$298,000	$344,500	$488,000	$497,800
Line of Credit, Current	$400,000	$300,000	$0	$0
Other Liabilities, Current	$71,000	$82,600	$72,600	$110,000
Liabilities, Current	$804,400	$738,100	$560,600	$607,800
Preferred Stock, Value, Issued	$0	$0	$0	$0
Common Stock, Value, Issued	$700	$800	$800	$800
Additional Paid in Capital, Common Stock	$2,549,000	$2,698,900	$2,798,000	$2,895,800
Accumulated Other Comprehensive Income (Loss), Net of Tax	$-12,800	$-3,400	$900	$-16,200
Treasury Stock, Common, Value	$2,579,200	$3,474,500	$4,260,400	$5,644,900
Retained Earnings (Accumulated Deficit)	$6,027,100	$7,222,200	$8,556,900	$9,164,800
Stockholders' Equity Attributable to Parent	$5,984,800	$6,444,000	$7,096,200	$6,400,300
Preferred Stock, Shares Authorized	10,000,000	10,000,000	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0	0	0
Common Stock, Shares Authorized	245,000,000	245,000,000	245,000,000	245,000,000
Common Stock, Shares, Issued	73,659,761	74,997,896	76,452,253	78,029,318
Common Stock, Shares, Outstanding	47,040,545	44,831,306	43,643,165	42,676,835
Treasury Stock, Common, Shares	26,619,216	30,166,590	32,809,088	35,352,483

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Net Income (Loss) Attributable to Parent	$984,800	$1,195,100	$1,334,700	$1,310,900
Net Cash Provided by (Used in) Operating Activities	$978,000	$1,327,100	$1,561,200	$1,685,200
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	$246,500	$489,500	$-140,100	$210,100
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$1,207,700	$1,697,200	$1,557,100	$936,900
Depreciation, Depletion and Amortization	$53,200	$72,500	$85,600	$91,500
Payments to Acquire Property, Plant, and Equipment	$230,400	$246,500	$520,500	$592,200
Share-based Payment Arrangement, Noncash Expense	$39,100	$144,000	$147,700	$155,400
Payments to Acquire Intangible Assets	—	—	$5,500	$5,500
Impairment of Long-Lived Assets Held-for-use	$3,600	$0	$21,700	$21,700
Deferred Income Tax Expense (Benefit)	$-64,400	$-64,100	$97,700	$149,300
Payments to Acquire Debt Securities, Available-for-sale	$2,514,300	$1,646,100	$3,405,400	$1,677,000
Other Noncash Income (Expense)	$4,900	$24,300	$19,700	$-23,100
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale	$2,137,300	$1,537,000	$1,583,900	$1,202,300
Proceeds from Sale of Debt Securities, Available-for-sale	$0	$831,800	$1,861,600	$1,903,900
Payments to Acquire Businesses, Net of Cash Acquired	$89,200	$0	$0	$0
Net Cash Provided by (Used in) Investing Activities	$-719,600	$417,200	$-551,300	$744,500
Increase (Decrease) in Accounts Receivable	$58,500	$400	$70,900	$-69,000
Payments for Repurchase of Common Stock	—	$1,000,000	$1,000,000	$2,500,000
Increase (Decrease) in Inventories	$13,600	$46,900	$52,600	$91,800
Proceeds from Lines of Credit	$0	$0	$200,000	$0
Increase (Decrease) in Accounts Payable and Accrued Liabilities	$57,100	$42,700	$97,900	$37,700
Repayments of Lines of Credit	$100,000	$400,000	$500,000	$0
Increase (Decrease) in Other Operating Assets and Liabilities, Net	$82,800	$55,600	$80,900	$108,100
Payments of Debt Issuance Costs	$2,700	$2,700	$11,500	$3,400
Proceeds from Stock Options Exercised	$98,000	$152,500	$173,900	$333,800
Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised	$6,600	$7,600	$9,200	$9,900
Payment, Tax Withholding, Share-based Payment Arrangement	$13,800	$12,200	$16,600	$59,900
Net Cash Provided by (Used in) Financing Activities	$-11,900	$-1,254,800	$-1,150,000	$-2,219,600
Interest Paid, Excluding Capitalized Interest, Operating Activities	$56,000	$40,200	$13,500	$7,700
Income Taxes Paid, Net	$332,500	$400,600	$313,300	$161,900
Capital Expenditures Incurred but Not yet Paid	$18,400	$22,200	$116,300	$154,200

United Therapeutics Corporation

Consolidated Statementsof Operations

Consolidated Balance Sheets

Consolidated Statementsof Cash Flows

United Therapeutics Corporation

Consolidated Statementsof Operations

Consolidated Balance Sheets

Consolidated Statementsof Cash Flows